TON - February 2022 Vol 15, No 1

From The Editors February 2022
The February issue of The Oncology Nurse-APN/PA (TON) features a variety of articles that specifically address topics of interest for nurses, navigators, and advanced practice providers caring for patients with cancer, including the latest results from clinical trials evaluating novel and FDA-approved therapies being used to extend survival and enhance quality of life. Read More ›

As the COVID-19 pandemic continues into 2022, advocacy groups have worked tirelessly to provide vital services to patients with cancer while facing numerous challenges, including reductions in staff and decreased funding. Read More ›

The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL). Read More ›

The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months aof the COVID-19 pandemic. Read More ›

Second-line therapy with trastuzumab deruxtecan (Enhertu; T-DXd) extended progression-free survival (PFS) and improved objective response rate (ORR) versus trastuzumab emtansine (Kadcyla; T-DM1) in women with HER2-positive metastatic breast cancer, including those with stable brain metastasis at baseline, according to a subgroup analysis of a phase 3 clinical trial. Read More ›

This section provides a brief overview of new cancer drugs and indications approved by the FDA between November 29, 2021, and December 15, 2021. Read More ›

Results from 2 single-center studies presented at the ASH 2021 Annual Meeting and Exposition showed that nearly 1 in 6 patients with hematologic diseases had no or low antibody response after a second COVID-19 vaccination, but that the mRNA 1273 COVID-19 vaccine induced a strong antibody response in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Read More ›

Two years of abiraterone acetate (Zytiga) plus prednisone added to androgen-deprivation therapy (ADT) improved metastasis-free survival and overall survival compared with ADT alone in men with nonmetastatic castration-sensitive prostate cancer, whereas the addition of enzalutamide (Xtandi) to ADT had no benefit, and much greater toxicity. Read More ›

ALK inhibitor therapy achieved “remarkable” response rates in a small study of patients with ALK-positive adult-onset neuroblastoma. Read More ›

Final results from the pivotal phase 3 KEYNOTE-355 trial showed that the addition of pembrolizumab (Keytruda) to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 with a combined positive score (CPS) ≥10. Read More ›

Page 1 of 2


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: